Head-To-Head Comparison: Belite Bio (BLTE) versus Its Peers

Belite Bio (NASDAQ:BLTE) is one of 992 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Belite Bio to similar businesses based on the strength of its profitability, institutional ownership, valuation, dividends, analyst recommendations, risk and earnings.

Volatility and Risk

Belite Bio has a beta of -1.62, meaning that its stock price is 262% less volatile than the S&P 500. Comparatively, Belite Bio’s competitors have a beta of 0.85, meaning that their average stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Belite Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-54.05%	-50.06%
Belite Bio Competitors	-2,613.34%	-229.90%	-29.69%

Insider and Institutional Ownership

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Belite Bio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	7	0	3.00
Belite Bio Competitors	5998	18433	43947	909	2.57

Belite Bio presently has a consensus target price of $44.83, suggesting a potential upside of 20.29%. As a group, “Pharmaceutical preparations” companies have a potential upside of 90.86%. Given Belite Bio’s competitors higher probable upside, analysts clearly believe Belite Bio has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Belite Bio and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Belite Bio	N/A	-$31.63 million	-30.06
Belite Bio Competitors	$1.68 billion	$149.77 million	-4.34

Belite Bio’s competitors have higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Belite Bio competitors beat Belite Bio on 9 of the 13 factors compared.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.